Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Bolt Biotherapeutics (BOLT) EBITDA Margin (2020 - 2025)

Bolt Biotherapeutics' EBITDA Margin history spans 6 years, with the latest figure at 329.55% for Q3 2025.

  • For Q3 2025, EBITDA Margin rose 97869.0% year-over-year to 329.55%; the TTM value through Sep 2025 reached 825.72%, down 16403.0%, while the annual FY2024 figure was 820.0%, 4644.0% up from the prior year.
  • EBITDA Margin for Q3 2025 was 329.55% at Bolt Biotherapeutics, up from 477.11% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 206.37% in Q1 2024 and bottomed at 5401.57% in Q4 2021.
  • The 5-year median for EBITDA Margin is 1142.73% (2023), against an average of 1496.75%.
  • The largest annual shift saw EBITDA Margin soared 404034bps in 2022 before it tumbled -70173bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 5401.57% in 2021, then skyrocketed by 75bps to 1361.23% in 2022, then skyrocketed by 38bps to 846.91% in 2023, then crashed by -54bps to 1308.24% in 2024, then skyrocketed by 75bps to 329.55% in 2025.
  • Per Business Quant, the three most recent readings for BOLT's EBITDA Margin are 329.55% (Q3 2025), 477.11% (Q2 2025), and 908.1% (Q1 2025).